GEN-MKT-18-7897-A
Dec 4, 2015 | Blogs, Life Science Research, Proteomics | 0 comments
A recent webcast by Charles Pineau, Director of Protim, IRSET, Rennes, France, demonstrates how you can use the OneOmics™ Platform as a “Click & Easy” workflow for integrating next-generation proteomics (NGP) data with next-generation sequencing (NGS) data. Dr. Pineau and his colleagues are interested in gaining new insights into human spermatogenesis and understanding the dialogue between germ cells and somatic cells. In previous research using rat samples, over 1400 unannotated transcripts were identified. Subsequent proteogenomic studies then showed that some of those transcripts encoded for novel proteins. The data analysis for that research was performed using the open source EMBOSS suite of tools.
In the current study, the researchers were interested in analyzing human samples and developing a more simplified workflow for data analysis. Using the SCIEX TripleTOF® 6600, and the Illumina HiSeq 2500, over 1100 new potential transcripts were identified with more than 2 peptides at FDR < 1%. The OneOmics Platform was used for data processing and analysis. Compared with the previous open source EMBOSS suite of tools used in the rat studies, the OneOmics Platform was about 75x faster. Additionally, another major benefit using the OneOmics Platform was the relative ease with which the data could be analyzed compared with the previous workflow which required extensive user customization by writing scripts and formatting files. This enabled the researchers to focus on the biology rather than the complications associated with formatting datasets and transformation of files. Ongoing studies are taking a subset of candidates and validating them using MRM studies, qPCR, and immunohistochemistry.
Comment below to get a demo OneOmics today.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network